Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CinnaGen daratumumab versus Darzalex in relapsed or refractory multiple myeloma
IRCT20150303021315N38Phase 3Recruiting
- Sponsor
- CinnaGen
- Start
- Nov 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of daratumumab, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by CinnaGen. Primary endpoint: Very good partial response or better rate. Started Nov 2025; status: recruiting.
02
Drugs
daratumumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on IRCT20150303021315N38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150303021315N38.